Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Key data on U.S. J&J, Moderna COVID-19 boosters weeks away, Fauci says

09/19/2021 | 01:29pm EDT

WASHINGTON, Sept 19 (Reuters) - Data needed to determine the advisability of booster shots of the Moderna Inc and Johnson & Johnson COVID-19 vaccines is just weeks away, President Joe Biden's chief medical adviser, Dr. Anthony Fauci, said on Sunday.

Health officials signaled they expected boosters would ultimately be recommended for a broad swath of the population, but urged Americans not to seek booster doses until they have FDA approval.

"We recommend that people wait until you get to the point where you fall into the category where it's recommended," he told CNN.

On Friday, a Food and Drug Administration advisory panel recommended a third shot https://www.reuters.com/world/us/us-covid-19-booster-debate-moves-fda-vaccine-advisory-committee-2021-09-17 of the two-dose Pfizer/BioNTech vaccine for people age 65 and older or at high risk of severe COVID-19, but declined to endorse boosters for the wider population.

Though the FDA is not bound by the panel's recommendation, it will take it into consideration when deciding whether to recommend a third round of shots.

"This is not the end of the story," Fauci told CNN's "State of the Union" program. "They're going to continue to look at this, literally in real time," Fauci added.

People who have received the two-dose Moderna vaccine or one-dose J&J vaccine are still awaiting guidance on possible booster shots.

"The actual data that we'll get (on) that third shot for the Moderna and second shot for the J&J is literally a couple to a few weeks away," Fauci told NBC's "Meet the Press" program.

"We're working on that right now to get the data to the FDA so they can examine it and make a determination about the boosters for those people," Fauci added.

More data may also show a broader need for booster shots across the general U.S. population, Fauci said.

The United States leads the world in total reported COVID-19 cases and deaths. Nearly 676,000 people have died during the pandemic in the United States, figures compiled by Reuters https://graphics.reuters.com/world-coronavirus-tracker-and-maps/countries-and-territories/united-states showed. An increase in U.S. cases and deaths in recent months has been most acute in areas with lower vaccination rates even as federal health officials implore vaccine holdouts to get their shots.

Biden announced in August https://www.whitehouse.gov/briefing-room/speeches-remarks/2021/08/18/remarks-by-president-biden-on-fighting-the-covid-19-pandemic-2 the government's intention to roll out booster shots for people age 16 and older, pending approval by the FDA and Centers for Disease Control and Prevention experts.

The FDA's decision-making process does not negate the White House's position favoring boosters, Fauci said, saying the plan was always contingent on FDA's regulatory process.

Dr. Francis Collins, director of the U.S. National Institutes of Health, said on the "Fox News Sunday" program that he expects it would "become clear over the next few weeks that administration of boosters may need to be enlarged," citing existing data from the United States and Israel indicating waning vaccine effectiveness over time.

The officials also signaled the timeline for vaccine authorization for children from 5-11 years old is in the coming weeks.

"For kids 5 to 11, the data is supposed to come in at the end of this month, and FDA will be working 24-7 to go through it," Collins said. "So we all hope that can happen in weeks, and not months."

(Reporting by Sarah N. Lynch, David Lawder and Chris Prentice; Editing by Will Dunham and Lisa Shumaker)


ę Reuters 2021
All news about MODERNA, INC.
05:20pU.S. administers over 415 mln doses of COVID-19 vaccines - CDC
RE
02:39pModerna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of Its ..
BU
11:56aSwitzerland Agency Approves Moderna and Pfizer/BioNTech Boosters
DJ
11:40aModerna Wins Swiss Regulator's Approval For Booster Dose of COVID-19 Vaccine
MT
11:31aModerna Signs MoU With African Union to Supply Up to 110 Million COVID-19 Vaccine Doses
MT
11:23aCOVID-19 vaccines safe for people with history of severe allergies, study finds
AQ
11:10aSWITZERLAND APPROVES MODERNA COVID B : Bloomberg
MT
10:13aModerna Secures Swiss Regulator's Approval For Booster Dose of COVID-19 Vaccine
MT
09:45aModerna Announces Swissmedic Authorizes Booster Dose of Moderna's COVID-19 Vaccine
BU
09:17aHealth Care Stocks Edge Higher Premarket Tuesday
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 374 M - -
Net income 2021 12 558 M - -
Net cash 2021 13 559 M - -
P/E ratio 2021 11,6x
Yield 2021 -
Capitalization 140 B 140 B -
EV / Sales 2021 6,18x
EV / Sales 2022 5,47x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Last Close Price 345,74 $
Average target price 295,79 $
Spread / Average Target -14,4%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.234.60%141 099
LONZA GROUP AG31.93%60 646
IQVIA HOLDINGS INC.43.58%49 145
SEAGEN INC.0.22%31 933
CELLTRION, INC.-38.02%25 328
ALNYLAM PHARMACEUTICALS, INC.53.63%23 730